24th Nov 2015 12:14
Ap27
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader | J.P. Morgan Securities LLC. |
Company dealt in | Pfizer Inc |
Class of relevant security to which the dealings being disclosed relate (Note 1) | Common Stock |
Date of dealing | 23 November 2015 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Class of relevant security: | Long | Short | ||||
Common Stock | Number | (%) | Number | (%) | ||
(1) Relevant securities | 5,273,651 0.09 | 3,750,883 0.06 | ||||
(2) Derivatives (other than options) | 1,239,408 0.02 | 2,496,887 0.04 | ||||
(3) Options and agreements to purchase/sell | 9.437.270 0.15 | 7,209,300 0.12 | ||||
Total | 15,950,329 0.26 | 13,457,070 0.22
| ||||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security: | Long | Short | ||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | ||||||
(2) Derivatives (other than options) | ||||||
(3) Options and agreements to purchase/sell | ||||||
Total | ||||||
Ap28
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchases/ sales
| Number of relevant securities | Price per unit (USD) |
Purchases
Sales | 300 200 500 200 400 500 400 913 800 879 1,721 1,700 2,000 1,800 2,200 2,500 3,637 2,800 18,839 700 3,100 4,400 200 5,100 4,902 400 1,400 4,321 500 18,335 5,900 5,100 4,200 900 3,000 664 6,600 1,000 4,000 1,200 300 6,200 800 1,500 300 6,100 82,639 2,700 2,696 604 64 700 5,800 104,925 300 500 1,100 200 900 400 1,300 1,300 500 1,342 6,783 1,200 1,200 125 300 2,500 500 2,800 500 4,100 200 3,515 1,900 800 2,000 800 2,900 300 1,300 5,450 189 300 6,600 3,600 3,400 200 4,200 900 6,649 3,600 2,400 1,600 1,875 1,100 700 300 1,100
200 300 700 100 100 164 30,098 200 100 7,202 200 100 100 64 | 31.0550 31.0650 31.0850 31.1050 31.1225 31.1250 31.1450 31.1550 31.1650 31.1750 31.1850 31.1950 31.1975 31.2000 31.2050 31.2150 31.2152 31.2250 31.2283 31.2307 31.2325 31.2350 31.2425 31.2450 31.2482 31.2525 31.2529 31.2550 31.2600 31.2605 31.2650 31.2750 31.2850 31.2856 31.2900 31.2927 31.2950 31.3000 31.3050 31.3100 31.3133 31.3150 31.3175 31.3200 31.3225 31.3250 31.3300 31.3350 31.3356 31.3399 31.3400 31.3425 31.3450 31.3453 31.3500 31.3525 31.3550 31.3625 31.3650 31.3725 31.3750 31.3850 31.3925 31.3950 31.4000 31.4050 31.4150 31.4200 31.4225 31.4250 31.4325 31.4350 31.4425 31.4450 31.4525 31.4550 31.4650 31.4750 31.4850 31.4925 31.4950 31.5000 31.5025 31.5050 31.5100 31.5125 31.5150 31.5250 31.5350 31.5400 31.5450 31.5525 31.5550 31.5650 31.5750 31.5850 31.5950 31.6050 31.6150 31.6250 31.6350
31.2200 31.2600 31.2743 31.2800 31.3000 31.3250 31.3300 31.3500 31.3900 31.4052 31.4150 31.4350 31.5450 31.5500 |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 5) | Number of relevant securities (Note 6) | Price per unit (USD) (Note 4) |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 4) |
Call Option | Selling | 500,000 | 32.50 | American | 27/11/15 | 0.07 |
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (USD) (Note 4) |
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature of transaction (Note 7) | Details | Price per unit (if applicable) (Note 4) |
Ap29
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 38.5(b) attached? (Note 8) YES
Date of disclosure | 24 November 2015 |
Contact name | Tung Le |
Telephone number | 020 7742 7272 |
Name of offeree/offeror with which connected | Allergan plc |
Nature of connection (Note 9) | Adviser to Allergan plc |
SUPPLEMENTAL FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 38.5(b)) OPEN POSITIONS (Note 1)
Product name, e.g. call option | Written or purchased | Number of relevant securities to which the option or derivative relates | Exercise price (Note 2)(USD) | Type, e.g. American, European etc. | Expiry date |
Call option
| Purchased | 30,000 | 35.00 | American | 20/01/17 |
Call option | Purchased | 70,000 | 37.00 | American | 20/01/17 |
Call option | Purchased | 363,900 | 35.00 | American | 15/01/16 |
Call option | Purchased | 700 | 38.00 | American | 15/01/16 |
Call option | Written
| 2,500 | 28.00 | American | 15/01/16 |
Call option | Written | 14,700 | 30.00 | American | 15/01/16 |
Call option | Written | 200 | 37.00 | American | 15/01/16 |
Call option | Written | 150,000 | 37.00 | American | 15/01/16 |
Call option | Written | 50,000 | 33.00 | American | 18/12/15 |
Call option | Written | 6,000 | 34.00 | American | 18/12/15 |
Call option | Written | 7,600 | 32.00 | American | 15/01/16 |
Call option | Purchased | 383,200 | 34.71 | European | 21/12/15 |
Call option | Purchased | 383,200 | 34.71 | European | 21/12/15 |
Call option | Purchased | 127,794 | 35.28 | European | 03/12/15 |
Call option | Purchased | 120,533 | 35.66 | European | 12/01/16 |
Call option | Purchased | 48,943 | 36.47 | European | 25/01/16 |
Call option | Written | 200,000 | 33.00 | European | 16/12/16 |
Call option | Written | 383,200 | 34.71 | European | 21/12/15 |
Put option | Purchased
| 30,000 | 35.00 | American | 20/01/17 |
Put option | Purchased | 20,000 | 35.00 | American | 20/01/17 |
Put option | Purchased | 4,300 | 30.00 | American | 15/01/16 |
Put option | Purchased | 2,800 | 28.00 | American | 15/01/16 |
Put option | Purchased | 300 | 32.00 | American | 15/01/16 |
Put option | Purchased | 150,000 | 30.00 | American | 16/09/16 |
Put option | Purchased | 100,000 | 36.00 | American | 18/03/16 |
Put option | Purchased | 32,900 | 32.00 | American | 15/01/16 |
Put option | Written | 9,200 | 33.00 | American | 19/02/16 |
Put option | Written | 19,100 | 31.00 | American | 19/02/16 |
Put option | Written | 5,300 | 23.00 | American | 15/01/16 |
Put option | Written | 100,000 | 30.00 | American | 15/01/16 |
Put option | Written | 5,600 | 25.00 | American | 15/01/16 |
Put option | Written | 250,000 | 28.00 | American | 15/01/16 |
Put Option | Written | 500,000 | 33.00 | American | 18/03/16 |
Put Option | Purchased | 200,000 | 33.00 | European | 16/12/16 |
Put Option | Written
| 117,900 | 35.00 | American | 17/06/16 |
Put Option | Written | 62,400 | 35.00 | American | 17/06/16 |
Put Option | Written | 71,300 | 35.00 | American | 17/06/16 |
Put Option | Written | 646,800 | 35.00 | American | 17/06/16 |
Put Option | Written | 154,500 | 35.00 | American | 17/06/16 |
Put Option | Written | 308,100 | 35.00 | American | 17/06/16 |
Put Option | Written
| 139,000 | 35.00 | American | 17/06/16 |
Put Option | Written
| 450,000 | 35.00 | American | 15/01/16 |
Callable Barrier Reverse Convertible Note | Purchased | 183,430 | 32.71 | N/A | 21/03/17 |
Callable Barrier Reverse Convertible Note | Purchased | 30,572 | 32.71 | N/A | 21/03/17 |
Auto-callable Barrier Reverse Convertible Note | Purchased | 45,984 | 32.62 | N/A | 17/03/17 |
Barrier Reverse Convertible Note | Purchased | 30,408 | 34.53 | N/A | 05/04/16 |
Equity Linked Note | Purchased | 6,740 | 29.67 | N/A | 03/02/16 |
Leveraged Accumulator | Purchased | 14,874 + | 29.12 | N/A | 12/09/16 |
Callable Barrier Reverse Convertible Note | Written | 183,430 | 32.71 | N/A | 21/03/17 |
Callable Barrier Reverse Convertible Note | Written | 30,572 | 32.71 | N/A | 21/03/17 |
Auto-Callable Barrier Reverse Convertible Note | Written | 45,984 | 32.62 | N/A | 17/03/17 |
Barrier Reverse Convertible Note | Written | 30,408 | 34.53 | N/A | 05/04/16 |
Equity Linked Note | Written | 6,740 | 29.67 | N/A | 03/02/16 |
Leveraged Accumulator | Written | 14,874 + | 29.12 | N/A | 12/09/16 |
Leveraged Accumulator | Written | 9,000+ | 31.70 | N/A | 04/03/16 |
Auto-callable Optimization Securities | Written | 7,851 | 27.60 | N/A | 25/06/20 |
Equity Linked Note | Written | 6,740 | 29.67 | N/A | 03/02/16 |
Callable Barrier Reverse Convertible Note | Written | 183,430 | 32.71 | N/A | 21/03/17 |
Callable Barrier Reverse Convertible Note | Written | 30,572 | 32.71 | N/A | 21/03/17 |
Auto-Callable Barrier Reverse Convertible Note | Written | 45,984 | 32.62 | N/A | 17/03/17 |
Barrier Reverse Convertible Note | Written | 30,408 | 34.53 | N/A | 05/04/16 |
Leveraged Accumulator | Written | 14,874 + | 29.12 | N/A | 12/09/16 |
Put Option | Purchased | 457,000 | 27.50 | N/A | 11/01/16 |
Callable Barrier Reverse Convertible | Purchased | 22,929 | 32.71 | N/A | 21/03/17 |
Auto-Callable Barrier Reverse Convertible Note | Purchased | 7,685 | 32.53 | N/A | 15/03/17 |
Auto-Callable Barrier Reverse Convertible Note | Purchased | 11,189 | 32.62 | N/A | 17/03/17 |
Barrier Reverse Convertible Note | Purchased | 178 | 2.44 | N/A | 05/04/16 |
Equity Link Note | Purchased | 31,133 | 32.12 | N/A | 15/12/15 |
Equity Link Note | Written | 31,133 | 32.12 | N/A | 15/12/15 |
Equity Link Note | Written | 31,133 | 32.12 | N/A | 15/12/15 |
Put Option | Purchased | 50,000 | 33.00 | American | 18/12/15 |
Call Option | Purchased | 200,000 | 34.00 | American | 04/12/15 |
Call Option | Purchased | 500,000 | 32.00 | American | 18/03/16 |
Call Option | Written | 1,000,000 | 32.00 | American | 18/03/16 |
Call Option | Written | 500,000 | 32.50 | American | 27/11/15 |
+ This instrument is physically settled, and the interest in shares has been calculated as the maximum number of Pfizer shares that the counterparty could be obliged to buy at the exercise price
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rules 8 and
38.5 of the Rules. If in doubt, consult the Panel.
Related Shares:
PFZ.L